Combination immunotherapeutic strategies for haematological cancers, NHMRC

Abstract

Patients with lymphoma cancers initially respond well to treatment, but later relapse with disease. The immune system can be effective at controlling cancer. A potential treatment option is to boost the natural immune response against cancer. This study investigates a novel vaccine that activates a certain immune cell, NKT cells, to fight lymphomas by delivering an NKT cell-activating molecule. Outcomes will allow assessment of combining an NKT-based vaccine with established treatments for lymphoma.

Journal

Title: Impact

Abbreviated Title: impact

Publisher: Science Impact, Ltd.

ISSN (Print): 2398-7073

Publication date Created: November 25 2017

Publication date (Print): November 25 2017

Volume: 2017

Issue: 10

Pages: 9-11

Article

DOI: 10.21820/23987073.2017.10.9

Copyright statement: © 2017

License:

This work is licensed under a Creative Commons Attribution 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Product

Self URI (article page): http://www.ingentaconnect.com/content/10.21820/23987073.2017.10.9